Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative ...

At the core of Oluwaseun’s research is the use of engineered viral vectors, which are designed ... Oluwaseun employs cutting-edge gene editing technologies to complement the viral delivery ...

Recent breakthroughs in gene ... vectors are discussed by Shitika et al. in “AAV-based Vector Improvements Unrelated to Capsid Protein Modification.” This research addresses the advancements in ...

Scientists looked at multiple techniques used to measure the modified viruses deployed in some gene ... vectors. The labs were asked to quantify the concentration of genetic material and viral ...

Today, gene therapy has broader applications, with trials covering many clinical problems including genetic diseases, cancer, infections such as HIV, and degenerative diseases. The transfer of genetic ...

Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...

An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...